LYKERA’s therapeutic strategy is based on a holistic view of cancer. A tumor mass is not only formed by proliferating cancer cells, but also receives nutrients via angiogenesis, gets support from surrounding stroma, and shares signalling factors with accessory cells. Therefore there are at least four tumor compartments that keep a constant crosstalk to allow cancer growth and cancer dissemination through metastasis. A key molecule controlling this crosstalk is the alarmin S100A4. Alarmins are soluble factors that are absent in normal tissues, but are overexpressed in aggressive cancers.
LYKERA’s scientists have generated a neutralizing antibody against S100A4 and proved that this first-in-class antibody blocks tumor progression and metastatic dissemination in several cancer indications, specially in the devastating, currently incurable, pancreatic cancer.